|
Delayed
Nasdaq
14:12:34 2026-08-24 EDT
|
5-day change | 1st Jan Change | ||
| 0.4043 USD | +0.82% |
|
+6.06% | -69.83% |
| 08-07 | Soligenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 06-08 | Soligenix Applies for Vaccine Development Funding for Bundibugyo Ebola Vaccine | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SOLIGENIX, INC. | Bio Therapeutic Drugs | +0.82% | +6.06% | -69.83% | -87.08% | -99.82% | 8.73M |  |  |  |
- Stock Market
- Stocks
- SNGX Stock
- Charts Soligenix, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
